Shoreline Biosciences is a biotechnology company that provides proprietary cell therapy technology platforms. It focuses on the induced pluripotent stem cells (iPSC) differentiation methods and genetic programming that enhance metabolic fitness and persistence of the engineered natural killer (NK) cells to improve anti-cancer activity offering iPSC-NK and iPSC-Macrophage cell platforms. The company aims to establish safe, effective, and affordable cell-based immunotherapies for cancer treatment using intelligently engineered iPSC-derived allogeneic cells.